Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared With Placebo in Pediatric Participants With Phelan-McDermid Syndrome

NCT07281079 is registered in ClinicalTrials.gov with Neuren Pharmaceuticals Limited as lead sponsor.

NCT NCT07281079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared With Placebo in Pediatric Participants With Phelan-McDermid Syndrome
Lead sponsor
Neuren Pharmaceuticals Limited
Phase
Phase 3
Overall status
Recruiting
Start date
November 12, 2025
Completion date
November 15, 2027
Enrollment
160 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

phelan-mcdermid syndrome